Characteristics of the patients with PD classified by motor subtype
| Tremor dominant | Intermediate | PIGD | p Value | |
| n (male/female) | 157 (81/76) | 45 (18/27) | 234 (98/136) | 0.13 |
| Age (years) | 68.1±7.2* | 68.6±8.1 | 70.2±8.1 | 0.025 |
| Disease duration (years) | 5.7±4.3* | 5.9±3.8* | 8.7±5.8 | <0.0001 |
| Hoehn and Yahr stage, n (%) | ||||
| Stage 1 | 27 (17.2)* | 7 (15.6) | 7 (3.0) | |
| Stage 2 | 111 (70.7)* | 28 (62.2) | 115 (49.1) | |
| Stage 3 | 18 (11.5)* | 10 (22.2) | 92 (39.3) | |
| Stage 4 | 1 (0.6)* | 0 (0.0) | 19 (8.1) | |
| Stage 5 | 0 (0.0)* | 0 (0.0) | 1 (0.4) | |
| MDS-UPDRS part II | 8.2±6.2* | 8.8±7.3* | 16.3±9.1 | <0.0001 |
| MDS-UPDRS part III | 28.9±13.2 | 21.9±12*¶ | 29.6±13.3 | 0.016 |
| MDS-UPDRS part IV | 0.9±1.8* | 1.4±2.4* | 2.9±4.0 | <0.0001 |
| MMSE | 28.2±2.0 | 28.3±1.9 | 27.8±2.0 | 0.14 |
| Depression, n (%) | 17 (10.8) | 6 (13.3) | 37 (15.8) | 0.37 |
| Initial presentation of motor symptoms, n (%) | <0.0001 | |||
| Tremor | 116 (73.9)* | 19 (42.2)¶ | 72 (30.8) | |
| Bradykinesia | 33 (21.0)* | 22 (48.9)¶ | 146 (62.4) | |
| Tremor and bradykinesia | 8 (5.1)* | 4 (8.9)¶ | 16 (6.8) | |
| Early onset, n (%) | 21 (13.4)* | 6 (13.3)* | 58 (24.8) | 0.011 |
| Falls during the past year, n (%) | 26 (16.6)* | 9 (20.0)* | 101 (43.2) | <0.0001 |
| Hallucinations, n (%) | 6 (3.8)* | 4 (8.9) | 30 (12.8) | 0.010 |
| Wearing off, n (%) | 32 (20.4)* | 14 (31.1) | 101 (43.2) | <0.0001 |
| De novo, n (%) | 16 (10.2) | 4 (8.9) | 14 (6.0) | 0.30 |
| LED (mg/day) | 359.1±254.8* | 415.8±283.8* | 588.9±401.0 | <0.0001 |
| Dopamine agonist, n (%) | 76 (48.4) | 19 (42.2) | 132 (56.4) | 0.11 |
| Levodopa, n (%) | 120 (76.4)* | 39 (86.7) | 206 (88.0) | 0.0082 |
*p<0.05 compared with the PIGD subtype; ¶p<0.05 compared with the tremor-dominant subtype.
LED, levodopa equivalent dose.; MDS-UPDRS, Movement Disorder Society revision of the Unified Parkinson's Disease Rating Scale; MMSE, Mini-Mental State Examination; PD, Parkinson’s disease; PIGD, postural instability and gait disturbance.